Cambridge biotechnology company developing three small-molecule drug candidates for obsessive-compulsive disorder. The programmes target distinct neurological mechanisms involving glutamate/GABA balance, AMPA receptor signalling and dopamine modulation, seeking more effective and faster-acting treatment options. Serenatis pairs its therapeutic work with precision biomarkers and computational approaches intended to identify relevant patient biology and guide treatment development. It is advancing preclinical work toward clinical trials, with AI engineering, clinical psychiatry and neuroscience expertise supporting its research.
